Therapies Offered at Residential Addiction Treatment Programs in the United States

Tamara Beetham; Brendan Saloner; Marema Gaye; Sarah E Wakeman; Richard G Frank; Michael L Barnett

doi:10.1001/jama.2020.8969

Therapies Offered at Residential Addiction Treatment Programs in the United States

JAMA. 2020 Aug 25;324(8):804-806. doi: 10.1001/jama.2020.8969.

Authors

Tamara Beetham¹, Brendan Saloner², Marema Gaye³, Sarah E Wakeman⁴, Richard G Frank⁵, Michael L Barnett³

Affiliations

¹ Department of Health Policy and Management, Yale University, New Haven, Connecticut.
² Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
³ Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
⁴ Department of Medicine, Massachusetts General Hospital, Boston.
⁵ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Abstract

This study uses simulated patient calls to a random sample of US residential addiction treatment facilities to investigate the availability of opioid agonist treatment (buprenorphine-naloxone) and nonpharmacologic therapies (eg, CBT) for opioid use disorder, and differences by for-profit vs nonprofit center status.

MeSH terms

Analgesics, Opioid / therapeutic use*
Behavior Therapy*
Behavior, Addictive / therapy
Health Care Surveys
Humans
Opioid-Related Disorders / drug therapy
Opioid-Related Disorders / rehabilitation
Opioid-Related Disorders / therapy*
Residential Treatment*
United States

Substances

Analgesics, Opioid

Abstract

MeSH terms

Substances

Grants and funding